Alkermes Q2 Revenue Surges 27% as GAAP Profit Collapses Amid Leadership Transition
Shares fall 5% to $50.05 as investors take profits; CEO Richard Pops hands reins to COO Blair Jackson
Alkermes plc reported second-quarter 2026 financial results on July 28, revealing a stark divergence between top-line momentum and bottom-line performance. Revenue rose 27 per cent year-on-year to $496.0 million, propelled by $411.7 million in proprietary net sales. Despite the growth, GAAP net income plummeted to $0.5 million from $87.1 million in the same period last year, weighed down by integration expenses and heightened investments in research and development as well as selling, general and administrative costs.
The company’s stock declined 5 per cent to $50.05 following the report, as investors took profits after a significant year-to-date rally. The revenue surge was anchored by strong commercial performances from VIVITROL, which generated $124.5 million, ARISTADA at $96.7 million, and LYBALVI, which saw a 12 per cent year-on-year increase to $94.0 million. Additionally, the newly integrated narcolepsy therapy LUMRYZ contributed $96.6 million in net sales, a figure that included an estimated $7 million inventory timing benefit.
Manufacturing and royalty revenues totalled $79.0 million, led by VUMERITY at $30.6 million and the INVEGA/XEPLION franchise at $27.5 million. Adjusted EBITDA grew to $139.2 million, underscoring the firm’s ability to generate earnings while funding expansion. However, elevated SG&A expenses, higher R&D spending, and gross-to-net adjustments compressed margins, causing the sharp drop in reported GAAP net income.
Concurrently, Alkermes announced a leadership transition. Chief Executive Officer Richard Pops will move to the role of Executive Chairman, while Chief Operating Officer Blair Jackson assumes the CEO position effective August 1. The change comes as the company manages the integration of LUMRYZ following its acquisition of Avadel Pharmaceuticals, a move that has increased the firm’s debt burden and reduced cash buffers.
Institutional interest in the stock has fluctuated, with hedge fund positions rising to 56 funds in the first quarter of 2026 from 45 in the fourth quarter of 2025. HealthInvest Partners AB held 213,329 shares valued at approximately $11.18 million, representing 3.01 per cent of its 13F portfolio, though it reduced its position by 13 per cent during the quarter. Investors are now looking toward upcoming pipeline readouts for ALKS 7290 in ADHD and alixorexton in idiopathic hypersomnia, alongside organic prescription trends for LUMRYZ under new leadership.
